For research use only. Not for therapeutic Use.
Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC50 value of 0.071 μM. Sovilnesib can be used for the research of cancer[1][2].
Sovilnesib (AMG 650; 0-10 pM; 96 and 144 h; cancer cell lines) has anti-proliferative activity and inhibits tumor cell growth in a dose-dependent manner[1].
Sovilnesib (AMG 650; 10-100 mg/kg; p.o. daily, for 45 d; female nude mice without thymus with OVCAR-3 xenografts) inhibits tumor growth, Lasting tumor regression and cure occurred in 50% of the animals, Sovilnesib has no apparent toxicity[1].
| Catalog Number | I036521 |
| CAS Number | 2410796-79-9 |
| Synonyms | 2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-(2-hydroxyethylsulfonylamino)benzamide |
| Molecular Formula | C26H34F2N6O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C26H34F2N6O4S/c1-18-16-22(31-24(29-18)34-12-8-26(27,28)9-13-34)30-23(36)20-3-2-19(32-39(37,38)15-14-35)17-21(20)33-10-6-25(4-5-25)7-11-33/h2-3,16-17,32,35H,4-15H2,1H3,(H,29,30,31,36) |
| InChIKey | KBDGEJDIHZDPHN-UHFFFAOYSA-N |
| SMILES | CC1=CC(=NC(=N1)N2CCC(CC2)(F)F)NC(=O)C3=C(C=C(C=C3)NS(=O)(=O)CCO)N4CCC5(CC5)CC4 |
| Reference | [1]. Payton MN, et, al. Kif18a inhibitors for treatment of neoplastic diseases. WO2021211549 [2]. Tamayo NA, et, al. Kif18a inhibitors. WO2020132648. |
